DUBLIN, June 2, 2016 /PRNewswire/ --
Research and Markets has announced the addition of the "Global Dermatology Market to 2022 - Innovative Pipeline and Increasing Uptake of Biologics to Diversify Treatment Options and Drive Strong Growth" report to their offering.
The global dermatology market was valued at $20.0 billion in 2015, and is projected to grow at a considerable Compound Annual Growth Rate (CAGR) of 7.73%, reaching $33.7 billion in 2022.
Key drivers of this growth will be the uptake of recently approved premium biologics, as well as promising late-stage products that are expected to be highly valuable.
Dermatological conditions are one of the most common types of disorders worldwide, and approximately one-third of the US population suffers from at least one active skin condition. For the past decades, the majority of the dermatology market has remained saturated with established products.
However, the clinical and commercial success of biologics in the treatment of psoriasis, as well as advancements in the understanding of the disease pathways of many dermatological conditions, have led to a renewed interest from pharmaceutical companies in the dermatology market, and subsequently the emergence of an innovative pipeline.
This report covers all dermatological disorders, but there is a particular focus on three key diseases: atopic dermatitis, acne vulgaris and psoriasis, as these conditions have the highest prevalence and the largest pipeline.
The dermatology market landscape is expected to change substantially with the advent of promising novel pipeline products.
Overall, there are 801 dermatology products in the pipeline, with biologics representing 37% of the pipeline, despite the fact that this molecule type represents only a small fraction of the marketed products landscape.
- Which molecular targets are most prominent within the pipeline?
- How do the key indications differ in terms of molecule type?
- How does the composition of the pipeline compare with that of the existing market?
- What mechanisms of action are most common for pipeline drugs?
Global revenues for the dermatology market are forecast to grow at a CAGR of 7.73%, from $20 billion in 2015 to $33.7 billion in 2022.
- Which products will contribute to market growth most significantly, and which will achieve blockbuster status?
- Will the current market leaders retain their dominance over the forecast period, and how is their revenue share of the dermatology market set to change?
- What CAGR will these companies register in the forecast period?
Key Topics Covered:
1 Tables & Figures
2.1 Therapy Area Introduction
2.3 Etiology and Pathophysiology
2.4 Co-morbidities and Complications
2.5 Epidemiology Patterns and Forecasts - Prevalence and Patient Segmentation
3 Key Marketed Products
3.2 Humira (adalimumab)
3.3 Remicade (infliximab)
3.4 Enbrel (etanercept)
3.5 Stelara (ustekinumab)
3.6 Neoral (cyclosporine)
3.7 Protopic (tacrolimus)
3.8 Elidel (pimecrolimus)
3.9 Elocon (mometasone furoate)
3.10 Differin (adapalene)
3.11 Metolate (methotrexate)
3.12 Clobex (clobetasol propionate)
4 Pipeline Landscape Assessment
4.2 Molecule Types in the Pipeline
4.3 Molecular Targets in the Pipeline
4.4 Clinical Trials
5 Multi-Scenario Market Forecast to 2022
5.1 Overall Market Size
5.2 Generic Penetration
5.3 Revenue Forecast by Molecular Target
6 Company Analysis and Positioning
6.1 Company Landscape
6.2 Marketed and Pipeline Portfolio Analysis
7 Strategic Consolidations
7.1 Licensing Deals
7.2 Co-development Deals
For more information visit http://www.researchandmarkets.com/research/lkdvzw/global
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets